Trial reportMolecular psychiatry2002
A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.
Trial report in Molecular psychiatry, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00495768 (Reducing Depressive Symptoms During HCV Therapy), which is not on this map. Cited by 98 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Reducing Depressive Symptoms During HCV Therapy: A Randomized Study
Who cites it
98 citing papers in PubMed, 2 syntheses or guidelines pooled it, 313 citations in OpenAlex.
- Antidepressant prophylaxis reduces depression risk but does not improve sustained virological response in hepatitis C interferon recipients without depression at baseline: a systematic review and meta-analysis.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2013Pooled it
- Pooled it
- Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: Findings from the CO-MED trial.Journal of psychiatric research · 2017Trial
- Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Trial
- Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection.Journal of gastroenterology and hepatology · 2012Trial
- No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C.Journal of affective disorders · 2011Trial
- Early prediction of major depression in chronic hepatitis C patients during peg-interferon alpha-2b treatment by assessment of vegetative-depressive symptoms after four weeks.World journal of gastroenterology · 2007Trial
- IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity.Molecular psychiatry · 2005Trial
- A quantitative assessment of depression and thyroid dysfunction secondary to interferon-alpha therapy in patients with hepatitis C.Journal of endocrinological investigationTrial
- Trial
- Inflammatory models of depression in rodents and humans.Frontiers in psychiatry · 2026Review
- CD4Frontiers in psychiatry · 2026Article
- Social inhibition in depressed patients is associated with an altered activation profile of the interleukin-6-inducible transcription factor STAT3.Brain, behavior, & immunity - health · 2025Article
- Toxicities Associated with Systemic Administration of Interleukin-6 in Wistar Albino Rats.Journal of experimental pharmacology · 2025Article
- Stress circuitry: mechanisms behind nervous and immune system communication that influence behavior.Frontiers in psychiatry · 2023Review
- Interferon therapy and its association with depressive disorders - A review.Frontiers in immunology · 2023Review
- Lower Levels of GABAergic Function Markers in Corticotropin-Releasing Hormone-Expressing Neurons in the sgACC of Human Subjects With Depression.Frontiers in psychiatry · 2022Article
- [Emotional disorder: a neglected symptoms of chronic liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021Review
- The immune system and psychiatric disease: a basic science perspective.Clinical and experimental immunology · 2019Review
- New direct-acting antivirals for hepatitis C treatment and neuropsychiatric symptoms in psychiatric risk groups.European journal of hospital pharmacy : science and practice · 2019Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interferon (IFN) therapy has been associated with the development of Major Depressive Disorder (MDD) when given to patients with hepatitis C (HCV). The incidence, time course, risk factors, and treatment of IFN-induced MDD are poorly understood. The objectives of the present study were to determine the incidence of IFN-induced MDD, as well as to determine the efficacy of open-label antidepressant treatment, in particular selective serotonin reuptake inhibitors (SSRIs) for IFN-induced MDD. Thirty-nine HCV patients on IFN therapy were monitored weekly using the Beck Depression Inventory (BDI). Those who became depressed were treated with citalopram, a SSRI antidepressant. Main outcome measures included the incidence of IFN-induced MDD, as well as response rates to antidepressants in those patients who developed IFN-induced MDD. Our results showed that 13 of 39 patients (33%) developed IFN-induced MDD. There were no differences in age, gender, past history of MDD, or substance use between those who became depressed and those who did not. However, there were significantly fewer African American patients in the depressed group. Patients who developed IFN-induced MDD were on IFN therapy for an average of 12.1 weeks prior to the development of MDD. Eleven of 13 patients (85%) were responsive to antidepressant treatment. We conclude that IFN-induced MDD is common in HCV patients. Health care providers should follow IFN-treated HCV patients for the development of MDD, particularly between the 2nd and 5th months of IFN therapy. SSRIs, in particular citalopram, are an effective treatment for IFN-induced depression in HCV patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.